Drug Profile
MGX 292
Alternative Names: MGX-292; Recombinant BMP 9 - Centessa PharmaceuticalsLatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator University of Cambridge
- Developer Centessa Pharmaceuticals
- Class Antihypertensives; Recombinant proteins
- Mechanism of Action Growth differentiation factor 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pulmonary arterial hypertension
Most Recent Events
- 19 May 2023 Pharmacodynamics data from a preclinical trial in Pulmonary-arterial-hypertension presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 30 Mar 2022 MGX 292 is still in preclinical development for Pulmonary-arterial-hypertension in the United Kingdom
- 30 Mar 2022 Centessa Pharmaceuticals plans to submit IND for Pulmonary Arterial Hypertension (PAH) in early 2023